OncLive® On Air

Non-Small Cell Lung Cancer

Triple Negative Breast Cancer

Clinical Trials

Immunotherapy

Breast Cancer

Small Cell Lung Cancer

FDA Approval

Chronic Lymphocytic Leukemia

Multiple Myeloma

Antibody Drug Conjugates

Bladder Cancer

Oncology

Chemotherapy

Pembrolizumab

Prostate Cancer

Colorectal Cancer

Surgery

Biomarker Testing

Metastatic Breast Cancer

BTK Inhibitors

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers,... more

32 ratings

Publishes	Daily	Episodes	500	Founded	8 years ago
Number of Listeners		Categories	Health & FitnessScience

Listen to this Podcast

Guests Hosts Reviews Talking Points

Latest Episodes

S17 Ep43: FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD

In today’s episode, we welcomed Charles E. Geyer, MD, to discuss recent FDA approvals of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the management of HER2-positive breast cancer. Dr Geyer is a professor of medicine and chief of Malignant He... more

1 Jul 2026 • 19 min

S17 Ep42: Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

In today’s episode, we spoke with Martin Schoen, MD, and Andrew W. Hahn, MD. Dr Schoen is a hematologist/oncologist and hospitalist at St. Louis Veterans Affairs Medical Center and Assistant Professor of Medicine at Saint Louis University. Hahn is an... more

1 Jul 2026 • 38 min

S17 Ep41: Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

In today’s episode, we welcomed Claire Harrison, MD, a professor of myeloproliferative neoplasms and clinical director at Guy's and St Thomas' NHS Foundation Trust in London, United Kingdom.

In the exclusive interview, Dr Harrison discussed manageme... more

30 Jun 2026 • 11 min

S17 Ep44: SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

30 Jun 2026 • 45 min

Key Facts

Accepts Guests

Contact Information

Podcast Host

Number of Listeners

Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Two Onc DocsSam and Karine

ASCO Daily NewsAmerican Society of Clinical Oncology (ASCO)

Oncology Brothers: Practice-Changing Cancer DiscussionsOncology Brothers

Oncology Today with Dr Neil LoveDr. Neil Love

Research To Practice | Oncology VideosDr Neil Love

Recent Guests

Michael J. Mauro, MD

MD discussing nalotinib formulation and FDA approval

Episode: S17 Ep36: FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Michael J. Mauro, MD

Zev A. Wainberg

MD, oncologist discussed in-depth KRAS-directed therapy in pancreatic cancer

Episode: S17 Ep35: KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD

Brad Haverkos

Associate professor of medicine hematology, University of Colorado, Anschutz

University of Colorado Anschutz Medical Campus

Episode: S17 Ep34: As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD

Joshua Richter

Associate Professor of Medicine; Director of Multiple Myeloma at Mount Sinai

Mount Sinai, Tisch Cancer Institute

Episode: S17 Ep32: Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD

Manmeet S. Ahluwalia

Oncologist discussing targeted therapies in gliomas

Episode: S17 Ep30: Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy

Ashley S. Margol

Oncologist discussing pediatric glioma therapies

Episode: S17 Ep30: Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy

Anthony Chi

Staff pathologist at MAP Kaiser Permanente

Mid-Atlantic Permanente Medical Group (Kaiser Permanente)

Episode: S17 Ep28: In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD

Archana Jadhav

Medical oncologist

Kaiser Permanente (Tysons, VA)

Monica Peravali

Medical oncologist

Kaiser Permanente (Largo, MD)

Hosts

Riley Kandel

Host of OncLive On Air

Aisling Wehner

Host of OncLive On Air

Reviews

4.5 out of 5 stars from 32 ratings

Best option for CME podcasts
Love the content! Easily the best platform for listening to CME and staying updated while on the go. Keep up the great work!
Apple Podcasts
5
Dlshaka
United Statesa year ago
My favorite podcast for oncology
This podcast provides excellent information to anyone who works in the medical field on oncology.
Apple Podcasts
5
Chiliman1986
United States6 years ago

Embed These Reviews on a Website

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Highly relevant for CME and clinical practice updates.

Strong focus on trials and biomarkers; great for sponsor alignment with oncologic education.

Consistently practical and data-driven, though dense for casual listeners.

Clear, credible expert voices with in-depth clinical context.

Top Health & Fitness Podcasts

The Dylan Gemelli PodcastDylan Gemelli

Passion Struck with John R. MilesPassion Struck with John R. Miles

Huberman LabScicomm Media

The Dr. Josh Axe ShowDr. Josh Axe

We're Out of TimeRichard Taite

The Dr. John Delony ShowRamsey Network

On Purpose with Jay ShettyiHeartPodcasts

Nothing much happens: bedtime stories to help you sleepWellness Loud

Tony Mantor: Why Not Me ?iHeartPodcasts

Biohack-itIman Hasan

Talking Points

Recent interactions between the hosts and their guests.

S16 Ep50: Medical Crossfire®: Translating Risk Into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast Cancer

Q: Is neoadjuvant checkpoint inhibition currently standard in ER-positive disease?

Checkpoint inhibitors are not approved in the neoadjuvant setting for ER-positive breast cancer yet; data in ER-low subsets suggest potential for future use, but not standard of care at this time.

S16 Ep50: Medical Crossfire®: Translating Risk Into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast Cancer

Q: How do you choose between CDK4/6 inhibitors when both could be suitable?

Preferred CDK4/6 inhibitor may depend on tolerability, comorbidities (e.g., QTc prolongation risk), duration considerations (two vs three years), and ongoing survival signals; often a patient-friendly, risk-based approach is used.

S17 Ep5: Medical Crossfire® Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Q: Would you utilize a combination like juridestrin plus everolimus if available, and do you see this becoming a preferred approach in ESR1 mutant patients?

Yes, many attendees felt that combining an mTOR inhibitor with a CDK4-6–inhibitor–free regimen or with an ESR1-targeted agent could be advantageous, particularly in ESR1 mutated disease, and anticipated supportive efficacy data for such combinations may drive adoption pending safety and regulatory approval.

S17 Ep5: Medical Crossfire® Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Q: If a patient has both an ESR1 mutation and a PI3K mutation, how do you decide between ESR1-targeted versus PI3K-targeted therapies?

Clinicians described leaning toward the dominant driver of the tumor biology: if the patient has been on an AI for a long time and develops ESR1 plus PI3K mutations, the team often prioritizes ESR1-directed approaches unless PI3K mutation drives rapid progression, in which case PI3K/mTOR-based therapy may be favored.

S17 Ep5: Medical Crossfire® Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Q: With the overall survival data that were presented for IMLU, did that sway you in any sort of way when you're thinking about monotherapy, about selection of oral SERDs?

The group discussed that OS signals are informative but practice still weighs prior lines, patient factors, and the tolerability of regimens; while OS data matter, they often reinforce but do not fully shift choices between ER degraders and oral SERDs, which depend on individual patient context.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About OncLive® On Air

What is OncLive® On Air about and what kind of topics does it cover?

A concise, clinician-focused show featuring in-depth conversations with academic oncologists and researchers about cutting-edge cancer care, trial results, and evolving treatment paradigms across thoracic, breast, GI, and gynecologic malignancies. Episodes emphasize biomarker-driven strategies, targeted therapies, and practical workflows for multidisciplinary teams, often discussing real-world implementation, patient impact, and access considerations. Noteworthy strengths include a strong emphasis on data interpretation, up-to-date trial context, and insights from leading cancer centers, making it especially valuable for oncology professionals seeking continuing education, clinical guidance, and context for emerging therapies. Potential lis... more

Where can I find podcast stats for OncLive® On Air?

Rephonic provides a wide range of podcast stats for OncLive® On Air. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to OncLive® On Air and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does OncLive® On Air get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for OncLive® On Air, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for OncLive® On Air?

Rephonic provides comprehensive predictive audience data for OncLive® On Air, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does OncLive® On Air have?

To see how many followers or subscribers OncLive® On Air has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to OncLive® On Air?

These podcasts share a similar audience with OncLive® On Air:

1. Two Onc Docs
2. ASCO Daily News
3. Oncology Brothers: Practice-Changing Cancer Discussions
4. Oncology Today with Dr Neil Love
5. Research To Practice | Oncology Videos

How many episodes of OncLive® On Air are there?

OncLive® On Air launched 8 years ago and published 500 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact OncLive® On Air?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for OncLive® On Air?

Rephonic pulls ratings and reviews for OncLive® On Air from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for OncLive® On Air?

Rephonic provides full transcripts for episodes of OncLive® On Air. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on OncLive® On Air?

Recent guests on OncLive® On Air include:

1. Michael J. Mauro, MD
2. Zev A. Wainberg
3. Brad Haverkos
4. Joshua Richter
5. Manmeet S. Ahluwalia
6. Ashley S. Margol
7. Anthony Chi
8. Archana Jadhav

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.

Try it free for 7 days